Nitrofurantoin and Prednisone: 258 reports.Nitrofurantoin and Pantoprazole: 144 reports.Nitrofurantoin and Oxycodone: 105 reports.Nitrofurantoin and Omeprazole: 393 reports.
Nitrofurantoin and Metformin: 195 reports.Nitrofurantoin and Macrobid: 115 reports.Nitrofurantoin and Lorazepam: 158 reports.Nitrofurantoin and Lisinopril: 302 reports.Nitrofurantoin and Lipitor: 214 reports.Nitrofurantoin and Lexapro: 105 reports.Nitrofurantoin and Levothyroxine sodium: 183 reports.Nitrofurantoin and Levaquin: 195 reports.Nitrofurantoin and Lansoprazole: 173 reports.Nitrofurantoin and Ibuprofen: 239 reports.Nitrofurantoin and Hydrochlorothiazide: 177 reports.Nitrofurantoin and Gabapentin: 231 reports.Nitrofurantoin and Furosemide: 318 reports.Nitrofurantoin and Fosamax: 154 reports.Nitrofurantoin and Folic acid: 246 reports.Nitrofurantoin and Fluconazole: 190 reports.Nitrofurantoin and Digoxin: 154 reports.Nitrofurantoin and Diazepam: 180 reports.Nitrofurantoin and Cymbalta: 127 reports.Nitrofurantoin and Coumadin: 134 reports.Nitrofurantoin and Clonazepam: 161 reports.Nitrofurantoin and Ciprofloxacin: 109 reports.Nitrofurantoin and Cephalexin: 163 reports.Nitrofurantoin and Celebrex: 130 reports.Nitrofurantoin and Baclofen: 214 reports.Nitrofurantoin and Azithromycin: 123 reports.Nitrofurantoin and Atenolol: 188 reports.Nitrofurantoin and Aspirin: 478 reports.Nitrofurantoin and Amoxicillin: 199 reports.Nitrofurantoin and Amlodipine: 140 reports.Nitrofurantoin and Alprazolam: 149 reports.Nitrofurantoin and Albuterol: 150 reports.Nitrofurantoin and Acetaminophen: 196 reports.Consult official guidance on the appropriate use of antibiotics when prescribing nitrofurantoin.Closely monitor for signs of pulmonary, hepatic, neurological, haematological, and gastrointestinal side effects during treatment, as previously advised in the summary of product characteristics (see below).Consider checking renal function when choosing to treat with nitrofurantoin, especially in the elderly.Only prescribe to such patients to treat lower urinary tract infection with suspected or proven multidrug resistant pathogens when the benefits of nitrofurantoin are considered to outweigh the risks of side effects. A short course (3 to 7 days) may be used with caution in certain patients with an eGFR of 30 to 44 ml/min/1.73m 2.Nitrofurantoin should not be used to treat sepsis syndrome secondary to urinary tract infection or suspected upper urinary tract infections.Nitrofurantoin is contraindicated in patients with an estimated glomerular filtration rate (eGFR) of less than 45 ml/min/1.73m 2.We remind you that antibiotic treatment of asymptomatic bacteriuria is not advised except during pregnancy and other special circumstances. We concluded that the existing contraindication is no longer supported and that the available evidence justified a revised contraindication against use in patients with an eGFR of less than 45 ml/min/1.73m 2. We also considered the risk of Clostridium difficile colitis associated with the widespread use of alternative broad-spectrum antibiotics (cephalosporins and flouroquinolones). We have reviewed the evidence for this contraindication in the context of increasing antibiotic resistance of lower urinary tract pathogens to standard therapy (trimethoprim and amoxicillin). Nitrofurantoin was previously contraindicated in patients with a creatinine clearance of less than 60 ml/min. This may reduce the antibacterial efficacy, increase the risk of side effects (eg, nausea, vomiting, loss of appetite), and may result in treatment failures. In patients with renal impairment, renal secretion of nitrofurantoin is reduced. The antibacterial efficacy in this infection depends on the renal secretion of nitrofurantoin into the urinary tract. Nitrofurantoin is an oral antibiotic for the treatment and prevention of urinary tract infections.